Stark Therapeutics

Early Stage

Stark Tx is changing the way the world treats chronic diseases with gene therapy

Analytics

Raised to Date: Raised: $25,882

Aggregate Commitments $

Platform

Wefunder

Start Date

07/28/2020

Close Date

04/05/2021

Min. Goal

$50,000

Max. Goal

$1,070,000

Min. Investment

$100

Security Type

SAFE

Funding Type

RegCF

Series

Seed

Valuation Cap

$7,000,000

Discount Rate

20%

Rolling Commitments $

Status
Not Funded
Reporting Date

04/04/2021

Days Remaining
Not Funded
% of Min. Goal

52%

% of Max. Goal

2%

Likelihood of Max
Not Funded
Avg. Daily Raise

$103

Momentum
Not Funded
Create a free account today to gain access to KingsCrowd analytics.
Location

Carlsbad, California

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Distribution Model

B2B2C

Margin

Low

Capital Intensity

High

Business Type

Growth

Stark Therapeutics, with a valuation cap of $8 million, is raising crowdfunding on Wefunder. The company uses gene therapy to treat chronic diseases. It is currently working on gene therapy for type II diabetes and a vaccine for COVID-19 targeting the nucleocapsid protein. Stark Therapeutics was founded by Anthony Stark in 2018 and has raised over $55,000 since its inception. The company’s crowdfunding round has a minimum target of $50,000 and a maximum target of $1,070,000, and the funds will be used for regulatory consulting, diabetes proof of concept study, vaccine viral challenge study, vaccine manufacturing, FDA consulting, and hiring production specialist. Stark Therapeutics is in the preclinical stage to evaluate the vaccine for COVID-19 and is prepared to scale to 100,000 doses in a few weeks after trial results.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$450

$450

 

 

Net Income

$0

$0

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$0

$0

Accounts Receivable

$0

$0

Total Assets

$0

$0

Short-Term Debt

$0

$0

Long-Term Debt

$0

$0

Total Liabilities

$0

$0

Financials as of: 07/28/2020
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$12.42 /month
billed annually
Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings (excluding risk)
Advanced company search ( with ratings)
Markets page filters and historical industry data
Get Edge Annual

Edge Pro

$41.58 /month
billed annually
Full site access including KingsCrowd's qualitative analyst reports.
Plan Includes:
Everything in Edge, plus
Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
Search and filter based on Analyst Reports
In-depth risk ratings for every raise
Get Edge Pro Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Analyst Report Analyst Report Methodology Article

Summary

Stark Therapeutics has been selected as an “Underweighted Deal” by KingsCrowd. If you have questions regarding our deal diligence and selection methodology, please reach out to hello@kingscrowd.com.

Problem

It is an understatement to say that the COVID-19 pandemic is one of the most impactful crises of this generation. Economic risks are significant to say the least. Over 700,000 worldwide have died, and the virus will likely rage on for several months. Virtually everyone on Earth has been affected in some way by COVID-19. 

 

Our primary hope for ending this massive disruption of modern life is a trustworthy vaccine. However, there are many questions as to the ultimate effectiveness of a preventative shot. Dr. Fauci warns that a vaccine may not be wholly effective. It’s also unclear how much the drug would cost and deciding who receives the vaccine first is thorny. 

Several companies are hustling to develop a vaccine. The Gates Foundation (among other large donors) has earmarked huge sums to incubate vaccine concepts. Still, as of early August 2020, no therapy has been approved for human use. The race is on: who will produce the coronavirus vaccine?

Solution

Stark Therapeutics is a brand-new gene therapy company tackling two challenges simultaneously: developing a vaccine for COVID-19 and producing a gene therapy technique to combat type II diabetes. Just this summer, Stark set up a lab and produced 1,000 doses of a pilot COVID-19 vaccine via pilot scale manufacturing. The company has initiated a preclinical study to evaluate the vaccine. Stark is prepared to scale to over 100,000 doses if the therapy is proven successful. 

 

The company is using innovative methods to develop both the vaccine and diabetes therapy. For the vaccine, Stark plans to use a protein from the SARS virus to train the body to fight COVID-19. Stark suggests that the effectiveness of this approach in SARS vaccination is a promising signal of success for a COVID vaccine. 

 

Stark’s diabetes therapy uses adeno-associated viruses and gene-inhibiting technology (interference RNA) to target two regulators of cell growth and metabolism, treating and reversing type II diabetes. This approach would supposedly reduce side effects of traditional diabetes therapies. It would also remain effective for ten or more years following a single administration.  

 

Stark Therapeutics raised $50,000 from the “Fight the Virus” challenge. That grant allowed the company to rapidly develop a lab and preclinical COVID vaccine. On the diabetes side of the business, Stark has received support from Michigan State University to launch an exploratory study on their genetic therapy. 

 

Stark Therapeutics has not yet generated any revenue. 

The Team

Stark Therapeutics has only one team member, founder and CEO Anthony Stark. Stark provides very little detail about his background. His LinkedIn page is blank with the exception of a degree in Human/Medical Genetics from the University of Wisconsin-Madison. 

Growth Plan

Stark shares that the company will likely require tens of millions of dollars in funding to fully scale its gene therapies and to generate revenue. The company estimates that the COVID vaccine will likely take six months or more before revenue generation. The diabetes therapy will take anywhere from two to four years. 

 

After the therapies are approved, Stark Therapeutics is hopeful that the vaccine could generate hundreds of millions in annual revenue. It projects that the diabetes treatment could generate billions based on the total market size of diabetes care. These figures are very rough estimates based on limited evidence of clinical effectiveness for both the vaccine and diabetes therapy. 

Rating

After careful consideration of the company’s areas of opportunity and seeming weaknesses, Stark Therapeutics has been ranked as an Underweight deal. Investors should consider three critical uncertainties when evaluating this opportunity: 

 

 

  • Founder inexperience: CEO Anthony Stark apparently has no background experience in genetic therapy or biotech entrepreneurship beyond a recent undergraduate degree in genetics. While Stark might be a brilliant scientist with the unique ability to develop a COVID vaccine on his own, it is more likely that he is ill-equipped to single-handedly develop lifesaving genetic therapies with little support or funding.  
  • Zero proof of concept in the preclinical phase: It is difficult for a non-scientist to evaluate the unique value proposition of a biotech company’s intellectual property. Most investors would hope for confirmation from clinical studies or regulatory agencies that the drugs being developed are effective. Unfortunately, Stark Therapeutics’ solutions are preclinical, so investors cannot fully evaluate the veracity of the company’s claims.
  • Crowded space for COVID vaccines: Virtually all major pharmaceutical companies are devoting significant resources toward the development of a COVID-19 vaccine. It is difficult for any startup company — particularly one with an inexperienced founder and limited resources — to compete with the likes of Merck and Johnson & Johnson as those giants work around the clock with thousands of scientists and billions of dollars to develop a therapy. 

 

 

Stark Therapeutics is simply too early-stage to adequately evaluate whether its genetic therapies will prove effective. This lack of proof in combination with other concerning signals (an inexperienced founder and the extent of competition in the COVID vaccine vertical) make Stark Therapeutics an Underweight deal. 

Create your first portfolio

Create your very own investment portfolio on KingsCrowd.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Stark Therapeutics on Wefunder
$
Platform: Wefunder
Security Type: SAFE
Valuation: $7,000,000

Follow company

Follow Stark Therapeutics on Wefunder
Withdrawn
Bullish / Bearish
You're Bullish on Stark Therapeutics on Wefunder

Thank you for your vote on Stark Therapeutics on Wefunder

Bullish / Bearish
You're Bearish on Stark Therapeutics on Wefunder

Thank you for your vote on Stark Therapeutics on Wefunder